In addition to the cited trails, a myriad of trials based on the targeting BCMA in MM ([60–65], CD19 in ALL [32, 66–74] and non-Hodgkin’s lymphoma (NHL) [69, 75–79], CD20 in BCL [70, 80–82], and CD22 in ALL [83–86] have shown the significant efficacy in the clinic. Here, CD22 is linked to non-Hodgkin lymphoma.